ストックスクリーナーアプリを入手
25.87
1.22%
-0.32
前日終値:
$26.19
開ける：
$25.96
24時間の取引高:
1.17M
Relative Volume:
0.94
時価総額：
$1.72B
収益：
$5.79M
当期純損益:
$-199.61M
株価収益率:
-8.5947
EPS:
-3.01
ネットキャッシュフロー:
$-188.48M
1週間 パフォーマンス:
+6.77%
1か月 パフォーマンス:
+17.16%
6か月 パフォーマンス:
+42.53%
1年 パフォーマンス:
-23.89%
1日の値動き範囲:
$25.43
$26.20
1週間の範囲:
$24.03
$26.46
52週間の値動き範囲:
$14.40
$34.50
Celldex Therapeutics Inc Stock (CLDX) Company Profile
CLDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
25.87 | 1.74B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-28 | 開始されました | Canaccord Genuity | Buy |
| 2025-03-20 | 開始されました | Morgan Stanley | Overweight |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Will Celldex Therapeutics Inc. rebound enough to break evenWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
Is Celldex Therapeutics Inc. reversing from oversold territory2025 Market Sentiment & Free Community Consensus Stock Picks - newser.com
How interest rate cuts could boost Celldex Therapeutics Inc. stockFed Meeting & Fast Gain Stock Trading Tips - newser.com
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Analyzing Celldex Therapeutics Inc. with risk reward ratio charts2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
How moving averages guide Celldex Therapeutics Inc. tradingM&A Rumor & Long-Term Safe Return Strategies - newser.com
Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cu... - ADVFN
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - 富途牛牛
Sovran Advisors LLC Purchases New Shares in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Mirador Capital Partners LP Raises Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Canaccord Genuity Group Reaffirms Buy Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat
Technical signs of recovery in Celldex Therapeutics Inc.July 2025 Final Week & Real-Time Stock Price Movement Reports - newser.com
Why Celldex Therapeutics Inc. is moving todayWeekly Stock Analysis & Daily Stock Trend Reports - newser.com
How correlated is Celldex Therapeutics Inc to the S P500Market Growth Report & Entry and Exit Point Strategies - خودرو بانک
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Key resistance and support levels for Celldex Therapeutics Inc.2025 AllTime Highs & Consistent Return Investment Signals - newser.com
Shorts Report: Will Celldex Therapeutics Inc benefit from geopolitical trendsTrade Risk Assessment & Weekly Setup with High ROI Potential - khodrobank.com
Celldex Therapeutics, Inc. $CLDX Stock Position Raised by Rhumbline Advisers - Defense World
Is Celldex Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Does Celldex Therapeutics Inc. show high probability of reboundGlobal Markets & Risk Controlled Daily Plans - newser.com
Quarterly Earnings: Can Celldex Therapeutics Inc disrupt its industryJuly 2025 Institutional & Target Return Focused Stock Picks - خودرو بانک
Momentum Shift: Will Celldex Therapeutics Inc benefit from government policyJuly 2025 Setups & Community Verified Swing Trade Signals - خودرو بانک
Should you hold or exit Celldex Therapeutics Inc. nowChart Signals & Weekly Top Stock Performers List - newser.com
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in CSU market - Investing.com Nigeria
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in CSU market By Investing.com - Investing.com South Africa
Celldex Presents Data Demonstrating Barzolvolimab Improves - GlobeNewswire
Celldex reports strong efficacy for urticaria drug regardless of IgE levels - Investing.com Canada
Celldex Therapeutics Says Barzolvolimab Data Shows Sustained Efficacy in Chronic Spontaneous Urticaria - MarketScreener
What are WSFSs technical support levelsQuarterly Portfolio Review & Verified Entry Point Detection - خودرو بانک
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - GlobeNewswire
71% Complete Response: Celldex's Novel CSU Drug Shows Breakthrough Results for All Patient Types - Stock Titan
Growth Report: Can Celldex Therapeutics Inc disrupt its industryTrade Risk Assessment & AI Forecasted Stock Moves - خودرو بانک
Published on: 2025-09-17 11:44:49 - khodrobank.com
Woodline Partners LP Sells 825,586 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Downgrade Watch: Will Celldex Therapeutics Inc benefit from geopolitical trendsWeekly Trend Report & Smart Swing Trading Techniques - خودرو بانک
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):